There are three editors in this journal: Professor Wei Yuquan, State Key Laboratory of Biotherapy and Clinical Oncology Research Center, West China Hospital, West China Medical College, Sichuan University.
Carol M, Institute of Genetics, Ohio State University, Columbus, USA. Professor Croce
Professor Zhang Kang, Center for Biomedicine and Innovation, Faculty of Medicine, Macau University of Science and Technology.
Among them, Professor Wei Yuquan is not only an oncologist and immunologist, but also an academician of China Academy of Sciences and a professor of Sichuan University. Wei Yuquan is mainly engaged in basic research, key technology development, product development and clinical treatment of tumor biotherapy. It is found that blocking HSP70 expression can induce cancer cell apoptosis in tumor microenvironment, immunotherapy, gene therapy and targeted drugs.
According to the latest classification of Chinese Academy of Sciences, STTT is excellent in medical science 1, biochemistry and molecular biology 1, and cell biology 2. STTT is an open access periodical. Although its name is signal transduction and targeted therapy, the journal has received a wide range of articles, including not only signal transduction, but also articles related to tumors or other major diseases, covering clinical research and laboratory research.
Finally, the page fee of this journal is 2680 US dollars /2 170 euros/1870 pounds. Not very expensive. STTT is a periodical backed by the mountains in the west of China. The editor-in-chief team is a combination of Chinese and western, and the review is quick and friendly.
With STTT consciously increasing the number of published articles, it is not impossible for the impact factors of journals to rise again next year. From this point of view, STTT is still quite trying. I hope I can help you.